During the last session, Poseida Therapeutics Inc (NASDAQ:PSTX)’s traded shares were 0.4 million, with the beta value of the company hitting 0.57. At the end of the trading day, the stock’s price was $2.83, reflecting an intraday loss of -6.60% or -$0.2. The 52-week high for the PSTX share is $4.27, that puts it down -50.88 from that peak though still a striking 35.34% gain since the share price plummeted to a 52-week low of $1.83. The company’s market capitalization is $274.88M, and the average intraday trading volume over the past 10 days was 0.48 million shares, and the average trade volume was 459.85K shares over the past three months.
Poseida Therapeutics Inc (PSTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PSTX has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.41.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Poseida Therapeutics Inc (NASDAQ:PSTX) trade information
Poseida Therapeutics Inc (PSTX) registered a -6.60% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.60% in intraday trading to $2.83, hitting a weekly high. The stock’s 5-day price performance is -8.71%, and it has moved by -15.27% in 30 days. Based on these gigs, the overall price performance for the year is 3.66%. The short interest in Poseida Therapeutics Inc (NASDAQ:PSTX) is 5.22 million shares and it means that shorts have 10.21 day(s) to cover.
The consensus price target of analysts on Wall Street is $15, which implies an increase of 81.13% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15 and $15 respectively. As a result, PSTX is trading at a discount of -430.04% off the target high and -430.04% off the low.
Poseida Therapeutics Inc (PSTX) estimates and forecasts
Statistics show that Poseida Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Poseida Therapeutics Inc (PSTX) shares have gone down -16.27% during the last six months, with a year-to-date growth rate less than the industry average at -14.60% against 16.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -17.10% this quarter and then drop -51.90% in the quarter after that. In the rating firms’ projections, revenue will increase 33.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 16.27M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 16.27M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 9.35M and 25M respectively. In this case, analysts expect current quarter sales to grow by 74.00% and then drop by -34.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.83%. While earnings are projected to return -3.10% in 2024, the next five years will return 2.70% per annum.
PSTX Dividends
Poseida Therapeutics Inc is due to release its next quarterly earnings 2024-Nov-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Poseida Therapeutics Inc (NASDAQ:PSTX)’s Major holders
Poseida Therapeutics Inc insiders own 27.68% of total outstanding shares while institutional holders control 55.27%, with the float percentage being 76.42%. FMR LLC is the largest shareholder of the company, while 131.0 institutions own stock in it. As of 2024-03-31, the company held over 14.47 million shares (or 16.0485% of all shares), a total value of $46.17 million in shares.
The next largest institutional holding, with 5.97 million shares, is of PENTWATER CAPITAL MANAGEMENT LP’s that is approximately 6.6253% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $19.06 million.
Also, the Mutual Funds coming in first place with the largest holdings of Poseida Therapeutics Inc (PSTX) shares are Fidelity Growth Company Fund and Fidelity Select Portfolios – Health Care . Data provided on May 31, 2024 indicates that Fidelity Growth Company Fund owns about 3.4 shares. This amounts to just over 3.50 percent of the company’s overall shares, with a $9.62 million market value. The same data shows that the other fund manager holds slightly less at 2.38, or about 2.45% of the stock, which is worth about $6.72 million.
